Johnson & Johnson (JNJ)vsPhreesia Inc (PHR)
JNJ
Johnson & Johnson
$260.86
+0.41%
HEALTHCARE · Cap: $614.36B
PHR
Phreesia Inc
$12.26
-0.08%
HEALTHCARE · Cap: $698.47M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 19660% more annual revenue ($97.93B vs $495.59M). JNJ leads profitability with a 21.5% profit margin vs 1.9%. JNJ trades at a lower P/E of 29.5x. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
PHR
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.3%
Fair Value
$139.75
Current Price
$260.86
$121.11 premium
Margin of Safety
+72.0%
Fair Value
$44.71
Current Price
$12.26
$32.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
1.9% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : PHR
The strongest argument for PHR centers on Debt/Equity, Price/Book. Revenue growth of 12.9% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PHR
The primary concerns for PHR are EPS Growth, Market Cap, Return on Equity. A P/E of 70.6x leaves little room for execution misses. Thin 1.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PHR is a value play — different risk/reward profiles.
PHR carries more volatility with a beta of 0.84 — expect wider price swings.
PHR is growing revenue faster at 12.9% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 44/100), backed by strong 21.5% margins. PHR offers better value entry with a 72.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Phreesia Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?